What are the advantages of revealing the domestic ring -shaped RNA new crown vaccine than the MRNA vaccine?

The 21st Century Economic Herald reporter Wei Xiao Shenzhen reported that recently, Yinyin's announcement has successfully completed more than 280 million yuan in Series A financing. Public information shows that Yuanyin creatures were founded in April 2021 by Professor Wei Wensheng of Peking University and focused on the research and application of circular RNA technology in the field of innovative drugs and innovative therapy.

The company has previously completed the angelic wheel and Pre-A round of financing. The three-round financing amount has exceeded 400 million yuan, including Tencent in the investment institutions. According to a third -party industrial and commercial information query platform, on April 24, the industrial and commercial changes in the biological creatures, and shareholders added Guangxi Tencent Entrepreneurship Investment Co., Ltd., with a shareholding ratio of about 8.67%. At the same time, the company's registered capital increased from approximately 1.5589 million yuan to approximately 2.156 million yuan.

Earlier, according to the School of Life Sciences of Peking University, the Wei Wensheng team established a technical platform for high -efficiency preparation of high -purity ring RNA in vitro, and designed a ring RNA vaccine for the new coronal virus spiny protein receptor domain (RBD), which is against Del to Del A variety of new coronary virus variants such as tower and Omikon have a broad -spectrum protection.

It is understood that, unlike the traditional linear RNA, most circular RNAs come from reverse editing from the outer sub -appendage, forming a closed -loop structure with covalent bonds. It is not affected by RNA external enzymes. The expression is more stable and it is not easy to degrade.

Zhang Jiancun, chairman of Guangzhou Hengnuokang Pharmaceutical Technology Co., Ltd., pointed out to the 21st Century Business Herald that the ring RNA -like RNA, such as MRNA, has better stability, but immunogenicity and scale production are still uncertain and difficult.

Obverse RNA advantage

In 2012, Julia Salzman, an associate professor at Biomedical and Biochemistry of Stanford University, discovered a large number of ring -shaped RNA dark substances in the human body, known as "major discovery of rewriting textbooks".

For a long time, the ring RNA has been considered as a by -product of the MRNA shear process and has no specific functions. However, in recent years, more and more studies have shown that ring RNA is not an by -product of MRNA cutting, but a class of RNA molecules that play an important role in cells.

It is understood that ring RNA is a special type of non -coding RNA molecules. Unlike the traditional linear RNA, most ring RNA comes from reverse editing of the outer sub -appendage, forming a closed -loop structure with covalent bonds. It is not affected by RNA external enzymes. The expression is more stable and it is not easy to degrade.

In terms of function, research in recent years has shown that CirCRNA molecules are rich in Microrna (MiRNA) binding sites, which play a role in the MiRNA sponge in the cell, and then relieve MiRNA's inhibitory effect on its target genes and increase the level of target genes; This mechanism is called a competitive endogenous RNA (CERNA) mechanism. By interaction with MiRNA associated with disease, CirCRNA plays an important regulatory role in diseases.

On May 17, 2022, Chen Lingling and Liu Chuxiao, Chen Lingling and Liu Chuxiao of the Institute of Molecular Cyan Science Innovation of the Chinese Academy of Sciences (Institute of Biochemistry and Cell Biology). This paper summarizes the circular RNA series of transformation application scenarios: such as the molecular sponge of the RNA adaptation, the MiRNA and the protein, the antonym RNA, the natural immune response in the regulatory cell, the protein translation carrier, and the disease -related molecular logo Reform and use the ring RNA to provide new ideas.

It is worth noting that MRNA is also linear RNA. Due to the advantages of fast production speed, low cost, and rapid response to virus variation, the MRNA vaccine was quickly developed and approved during the new crown period. Reporters from the 21st Century Economic Herald pointed out that solving the technical difficulties of domestic MRNA drug research and development in "raw materials, technology, and delivery systems" are critical to establish a safe, efficient and economical MRNA production platform.

Wei Wensheng once pointed out that the modification and delivery technology of the MRNA vaccine occurred in foreign institutions, which restricted the development and application of my country's MRNA vaccine and its treatment technology. Therefore, it is urgent to develop new and efficient vaccine technologies.

Many people in the industry pointed out that the ring RNA has obvious advantages compared to MRNA. Yang Yan, the co -founder and chief technology officer of the ring code biology, pointed out that the ring RNA has the characteristics of better thermal stability, longer medicinal time, and more special organizational expression. It is an ideal platform for the next generation of MRNA drug development. By creating a complete R & D and process system, the establishment of a win -win ecosystem will promote the implementation of ring -shaped RNA technology.

Despite the obvious advantages of ring RNA, industrialization also faces many problems, such as ringing, translation, preparation, mass production, etc.

It is worth noting that although the circular RNA exists in the nuclear creature, one of the key steps to be prepared in vitro in vitro to achieve industrialization. Wei Wensheng proposed that the current method and purification strategy of RNA are not yet mature, and the impact of potential immunogenicity on the development of vaccines is unclear. Many unknown factors restrict the development and application of ring RNA.

What are the companies in China?

In March 2022, the research papers entitled "Circular RNA Vaccines Against Sars-Cov-2 and Emerging Variants" in Cell Magazine. The Wei Wensheng team first established a technical platform for high -efficiency high -purity ring RNA in vitro. For the new coronary virus and its mutant strains, the ring -shaped RNA vaccine coded the new coronary spinesal protein receptor domain (RBD).

Experiments have proved that the vaccine can induce high -level new coronary virus neutralized antibodies and specific T cell immune responses in mice and Ganges monkeys, and can effectively reduce the virus load of the Ganges monkey lung infected by the new coronor virus. Significantly alleviate the symptoms of pneumonia caused by new coronal virus infection.

Wei Wensheng and others pointed out in the above -mentioned research papers that the ring -shaped RNA vaccine that prepared in the study targeting the new crown virus Delta has a broad -spectrum protection for a variety of new crown virus variants. The vaccine can be used as a broad -spectrum protection force The new crown candidate vaccine also provides a reference for the development and vaccination strategy of the current new crown mutant plant.

At the same time, it believes that the platform -type technology has a wide range of application prospects in infectious diseases, autoimmune diseases, rare diseases, and cancer prevention or treatment.

On June 21, Yuanyin's announcement was successfully completed by more than 280 million yuan in Series A financing. The financing was co -invested by a well -known industrial investment institution and Heyu Capital. Sherba Investment and Sanzheng Health Investment and Investment and Sanzheng Health Investment and Qianqian Capital continued to invest. In this regard, Wei Wensheng said that it will accelerate the clinical application of the ring -shaped RNA new crown vaccine.

It is reported that Yuanyin Bio has currently established preventive and therapeutic new drug product pipelines, and is committed to solving the disease needs that have not been met in clinic. In November 2021, Yuanyin announced the completion of exceeding 100 million yuan Pre-A round of financing, led by Quanchuang Capital, and thousands of capital follow-up.

It is also another domestic ring -shaped RNA therapy company that has obtained financing after the ring code. Earlier, the two ring RNAs, the two ring RNAs of ORNA Therapeutics and Laronde, received widespread concern to the circular RNA therapy. Among them, Laronde's round A and B financing obtained Flagship Pioneering of 50 million and US $ 440 million on May 11, 2021, respectively.

It is reported that the ring code creature was founded in 2018 and is a startup based on a ring -shaped RNA development nucleic acid drug. In 2021, the company completed the angel round and Pre-A round of financing. Investors include Kaitai Capital, Xingze Capital, Dangerous Fengfeng, Kunlun Capital, and Yifeng Capital. At present, it is undergoing a round of financing, for the construction of GMP workshop and process development.

On May 31, 2022, the cyclic biology released its latest development -based RNA circular technology on the Biorxiv website. This technology uses the cyclicization of GROUP II INTRON's self -scissor activity catalytic RNA, reacts efficiently and does not need to add auxiliary materials such as proteases, GTP, and no non -design sequence in its final product. This method can achieve high -efficiency industrial -grade production of ring RNA, which has a significant advantage over the industry's connection enzymes or PIE connection methods.

The paper points out that this study provides a general technology platform for high -efficiency ring -shaped RNA molecules, and also shows the potential of ring -shaped RNA molecules as the new generation MRNA therapy.

It is worth noting that the domestic circular RNA production and research service provider Jicai Bio is also shifting from service to the treatment target for developing diseases with major functions based on major functions.

Jicai Bio was established in June 2010 and is committed to RNA -related product research and development services. It is the earliest company in China to deploy this field. It started with CRO and CDMO services providing ring RNA gene therapy, mainly focusing on the core RNA core technology and complete circular RNA research system.

In an interview with the media, Liu Ming, CEO, revealed that in addition to the circular RNA CRO service, Jicai Bio will also develop disease targets based on the early discovery of circular RNA translation products with major functions.

Generally speaking, the current domestic circular RNA drug research and development company has less information. According to incomplete data statistics, most companies involving circular RNA related directions in China are mostly based on scientific research services and disease testing as their main business.

- END -